Gynecologic Cancers

Findings from a phase 2 study demonstrated encouraging clinical activity and a manageable safety profile when patients with advanced cervical cancer were treated with second-line balstilimab and zalifrelimab.

Treatment with tamoxifen for primary breast cancer may result in increased risk of developing subsequent uterine cancer by activating the PI3K pathway.

A secondary analysis of a clinical trial indicated that women who were human immunodeficiency virus–positive and underwent loop electrosurgical excision procedure for cervical intraepithelial neoplasia had an increased likelihood of clearing high-risk human papillomavirus than women who underwent cryotherapy.

Camrelizumab plus apatinib demonstrated efficacious anti-tumor activity and could be a worthwhile salvage therapy in high-risk chemorefractory or relapsed gestational trophoblastic neoplasia.

The FDA has approved the use of pembrolizumab plus chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer who have PD-L1 expression identified via an FDA-approved test.

Patients who were carriers of pathogenic variants of for BRCA1/2 had a better physical and mental quality of life after undergoing risk-reducing salpingectomy compared with risk-reducing salpingo-oophorectomy.

Women who received a total abdominal hysterectomy plus chemotherapy showed better survival then those women who received chemotherapy alone for uterine cancer with distant organ metastasis.

Use of economic coping mechanisms were associated with scoring 26 or lower on the COST analysis, or Comprehensive Score for Financial Toxicity, in patients being treated for gynecologic cancers.

The phase 2 KEYNOTE-158 trial has demonstrated promising responses in patients with microsatellite instability–high/ mismatch repair deficient advanced endometrial carcinoma, and led to the FDA accepting a review of a new supplemental biologics license application for the drug.

Women with gynecologic cancer who experience an improvement of social needs such as companionship and food insecurity could experience improved outcomes.

Clinical activity of the combination of pertuzumab and trastuzumab in seen in patients with ERBB2/ERBB3 overexpressing uterine cancers.

Results presented at part of the European Society for Medical Oncology Virtual Plenary show positive results of a phase 3 trial comparing cemiplimab with chemotherapy for previously treated cervical cancer.

In the advanced treatment setting, an FDA decision has indicated that the combination of pembrolizumab and lenvatinib may soon be available for certain patients with endometrial tumors and renal cell carcinoma.

Data examining thermal ablation for women with a total of 119 metastatic gynecologic tumors found the therapy was safe and effective in the local control of these tumors.

Patients with heavily pretreated vulvar squamous cell carcinoma experienced responses with pembrolizumab monotherapy in a nonrandomized phase 2 trial, regardless of PD-L1 status.

Hardesty detailed her expectations for the focus of the conference and the exciting topical opportunities presented this year’s SGO Annual Meeting compared with past years.

A subanalysis of the PRIMA/ENGOT-OV26/GOG-3012 trial found that quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo.

A study of patients with gynecologic cancer and COVID-19 found that neither having cancer nor receiving treatment for it worsened COVID-19 outcomes.

Within this study, satisfaction was markedly higher in those treated with apixaban, and adherence rates appeared to be similar between both modalities in women undergoing surgery for gynecologic cancer.

Researchers from a study published in Cancers discovered a new method of detecting endometrial cancer in women via a simple, non-invasive blood test.

A recent clinical trial’s results found that a targeted drug known as adavosertib caused tumors in nearly 30% of patients examined with uterine serous carcinoma, a hard-to-treat form of uterine cancer.

This study found that raising the awareness of general practitioners and highlighting the importance of encouraging immigrant women to participate in cervical cancer screening is a feasible and effective strategy to increase participation in the program.

Agenus received approval from the FDA for fast track designation of balstilimab monotherapy and balstilimab and zalifrelimab combination therapy for the treatment of metastatic cervical cancer.

The FDA granted priority review to pembrolizumab monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic TMB-high solid tumors who have progressed following prior treatment and who have no satisfactory alternative treatment options.

Though inflammatory bowel disease patients are generally at higher risk of HPV-related cancers, this data did not support intensified screening for vulvar or vaginal malignancies in female IBD patients.